Page 1

CASTLE BIOSCIENCES NEWS RELEASE Castle Biosciences Announces Third Quarter 2021 Results 11/8/2021 Q3 2021 revenue grew by 54 % over the prior year quarter to $ 23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $ 89-93 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD , Texas -- ( BUSINESS WIRE ) -- Castle Biosciences , Inc. ( Nasdaq : CSTL ) , a company applying innovative diagnostics to inform disease management and improve patient outcomes , today announced its financial results for the third quarter and nine months ended Sept. 30 , 2021 . " The Castle team achieved another quarter of strong growth in revenue and test report volume , despite the diagnoses of cutaneous melanoma being down by approximately 16 % compared to historical pre - COVID third quarter 2019 levels , ” said Derek Maetzold , president and chief executive officer of Castle Biosciences . “ From the onset of the pandemic , we made the strategic decision to accelerate investments in our growth initiatives , including the expansion of our commercial team and our R & D programs - both for our commercial and pipeline tests . And as a result , we have seen excellent progress across our key priorities . Our body of evidence supporting our tests continues to grow , with consistent data further demonstrating the potential of our tests to provide valuable , clinically actionable information to clinicians and patients . We doubled our dermatology facing commercial team in the second quarter of 2021. They were fully trained as of July 1 , 2021 , enabling the promotion of all of our skin cancer genomic tests in all U.S. geographies . The team grew their experience and territory knowledge in the third quarter , and we expect them to continue toward optimal productivity , which we believe takes about two quarters . 1